Aptamer-modified polymeric materials for the binding of factors in a wound environment
Aptamer-modified polymers and materials thereof, used for binding factors in a wound bed. The aptamer-modified materials can be polypeptides conjugated to polymer foam materials and used, for example, as dressings, wound inserts, or pads.
1. A wound dressing comprising a polymer foam substrate conjugated to a polypeptide, wherein the polypeptide comprises a sequence at least 90% identical to SEQ ID NO:1 or a sequence at least 90% identical to SEQ ID NO: 2.
2. The wound dressing of claim 1 , wherein the polypeptide is covalently attached to the polymer foam.
3. The wound dressing of claim 1 , wherein the polypeptide is attached via one or more linkers.
4. The wound dressing of claim 3 , wherein the polypeptide is attached to the polymer foam through a thioether linkage.
5. The wound dressing of claim 1 , wherein the amino or carboxyl terminus of the polypeptide comprises a polyethylene glycol (PEG) spacer-cysteine residue.
6. The wound dressing of claim 3 , wherein the linker is an N-(e-maleimidocaproyloxy) sulfosuccinimide ester-derived linker (EMCS-derived linker) or a sulfo-EMCS-derived linker.
7. The wound dressing of claim 6 , wherein the polymer foam comprises a substituted silyl derived linker.
8. The wound dressing of claim 7 , wherein the substituted silyl derived linker is derived from aminoundecyltriethoxysilane or aminopropyldiisopropylethoxysilane.
9. The wound dressing according to claim 1 , further comprising a growth factor, chemokine or cytokine bound to the wound dressing.
10. A wound dressing comprising a polyurethane foam substrate, wherein the polyurethane foam substrate comprises a co-polymer, and wherein the co-polymer comprises a repeat unit formed by polymerization of a pre-polymer and an aminoglycoside, and further comprising an aptamer covalently attached directly or via one or more linkers to the repeat unit of the co-polymer; wherein the pre-polymer comprises an isocyanate and the aminoglycoside is selected from the groups consisting of chitosan, glucosamine, neomycin, dibekacin, kanamycin, tobramycin, streptomycin, and gentamicin.
11. The wound dressing of claim 10 , wherein the polyurethane foam substrate is a reticulated open-celled foam.
12. The wound dressing of claim 10 , wherein the aptamer is attached to the polymer foam substrate via one or more linkers.
13. The wound dressing of claim 12 , wherein the aptamer is covalently attached to the one or more linkers through a thioether linkage.
14. The wound dressing of claim 12 , wherein the linker is an N-(e-maleimidocaproyloxy) sulfosuccinimide ester-derived linker (EMCS-derived linker) or a sulfo-EMCS-derived linker.
15. The wound dressing of claim 12 , wherein the linker is a substituted silyl-derived linker.
16. The wound dressing of claim 15 , wherein the substituted silyl-derived linker is derived from aminoundecyltriethoxysilane or aminopropyldiisopropylethoxysilane.
17. A method for treating a wound comprising contacting a wound site with a wound dressing of claim 1 .
18. A method for treating a wound comprising contacting a wound site with a wound dressing of claim 10 .